Clearmind Medicine (CMND) Total Non-Current Liabilities (2021 - 2026)
Clearmind Medicine (CMND) posted quarterly Total Non-Current Liabilities of $44347.0 for Q2 2026, down 92.09% year-over-year from $560723.0 in Q2 2025, and down 96.14% quarter-over-quarter from $1.1 million in Q1 2026.
Clearmind Medicine (CMND) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Clearmind Medicine's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $44347.0 for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities fell 92.09% year-over-year to $44347.0; the TTM figure through Apr 2026 stood at $44347.0 (down 92.09% YoY), while the FY2025 annual figure was $2.5 million, up 15258.56% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at $44347.0, down from $1.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $5.0 million in Q4 2023, with the low at $6903.0 in Q1 2025.
- The 5-year median for Total Non-Current Liabilities is $468165.0 (2024), against an average of $826700.2.
- The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities plunged 99.67% in 2024, then surged 16535.94% in 2026.
- Clearmind Medicine's Total Non-Current Liabilities stood at $550246.1 in 2022, then soared by 803.2% to $5.0 million in 2023, then slumped by 99.67% to $16416.0 in 2024, then jumped by 15258.56% to $2.5 million in 2025, then slumped by 98.24% to $44347.0 in 2026.
- Business Quant data shows CMND's Total Non-Current Liabilities at $44347.0 in Q2 2026, $1.1 million in Q1 2026, and $2.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - | 44,347.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 44,347.00 |
| Jan 31, 2026 | 1.15 Mn |
| Oct 31, 2025 | 2.52 Mn |
| Jul 31, 2025 | 725,178.00 |
| Apr 30, 2025 | 560,723.00 |
| Jan 31, 2025 | 6,903.00 |
| Oct 31, 2024 | 16,416.00 |
| Jul 31, 2024 | 25,578.00 |
| Apr 30, 2024 | 468,165.00 |
| Jan 31, 2024 | 30,507.00 |
| Oct 31, 2023 | 4.97 Mn |
| Jul 31, 2023 | 347,602.00 |
| Apr 30, 2023 | 858,715.00 |
| Jan 31, 2023 | 126,666.50 |
| Oct 31, 2022 | 550,246.09 |
| Oct 31, 2021 | 6,570.32 |